In a report released yesterday, Douglas Miehm from RBC Capital assigned a Buy rating to Bausch + Lomb Corporation (BLCO – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $16.60.
According to TipRanks, Miehm is an analyst with an average return of -2.2% and a 41.04% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Bausch Health Companies, and Aurinia Pharmaceuticals.
In addition to RBC Capital, Bausch + Lomb Corporation also received a Buy from Bank of America Securities’s Craig Bijou in a report issued yesterday. However, on the same day, Needham maintained a Hold rating on Bausch + Lomb Corporation (NYSE: BLCO).
See Insiders’ Hot Stocks on TipRanks >>
BLCO market cap is currently $5.12B and has a P/E ratio of -22.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch + Lomb Corporation (BLCO) Company Description:
Bausch & Lomb Corp is a global eye health company dedicated towards protecting and enhancing the gift of sight for millions of people around the world. It holds portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
Read More on BLCO:
- BLCO Earnings: Bausch + Lomb Outperforms in Q4, Shares Jump
- Emergent BioSolutions appoints Papa as new president, CEO
- Bausch + Lomb sees FY24 reveue $4.600B-$4.700B, consensus $6.14B
- Bausch + Lomb reports Q4 adjusted EPS 24c, consensus 24c
- Bausch Health price target lowered to $14 from $16 at Jefferies
